Danziger Asaf 4

What Happened Asaf Danziger, a director of NovoCure Ltd (NVCR), acquired 268 ordinary shares on June 30, 2026, at $11.15 per share, for a total purchase value of approximately $2,988. The shares were acquired through NovoCure's 2025 Employee Share Purchase Plan (ESPP); the filing classifies the transaction as an acquisition (code A).

Key Details

• Transaction date and price: 2026-06-30 at $11.15 per share; total ≈ $2,988.
• Shares acquired: 268 ordinary shares.
• Shares owned after transaction: Not disclosed in the Form 4 filing.
• Footnotes: (F1) Voluntary reporting of ESPP purchase for the Jan 1–Jun 30, 2026 purchase period; transaction exempt under Rule 16b-3(c). (F2) Shares purchased at 85% of the issuer's closing price on Jan 1, 2026 per the ESPP.
• Filing timeliness: Form 4 was filed on 2026-07-01 for a 2026-06-30 transaction — no late filing flag indicated.

Context This was a routine ESPP purchase (discounted employee stock plan) rather than an open-market buy or option exercise. ESPP purchases are common, provide a set discount (here 85% of the Jan 1, 2026 closing price), and are often part of regular employee compensation/savings programs. The dollar amount is small (~$3k), so while purchases can be more informative than sales, this particular transaction is a modest, routine acquisition.